← Leaderboards
Paul J Kenny
Icahn School Of Medicine At Mount Sinai
$51,539,568
Attributed
$79,427,715
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12M · FY2007–25$20M$15M$10M$5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$87,742,548 · 25
By mechanism
R01$31,055,562 · 11
U01$26,168,084 · 3
P01$11,931,240 · 5
UH3$8,945,352 · 2
UG3$3,979,720 · 1
R37$3,330,121 · 1
Top collaborators
- Theodore M Kamenecka13 shared
- David J Volsky9 shared
- Jon Martin Lindstrom6 shared
- Claes Robert Wahlestedt6 shared
- Louis Daniel Scampavia4 shared
- Hongkui Zeng4 shared
- Michael Jackson2 shared
- Patrick Robert Griffin1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Ana C. Pereira$7,556,161
- Meghan Elizabeth Flanigan$787,478
- Scott J Russo$23,138,406
- Freddyson J Martinez-Rivera$892,080
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainResponseCellsNeuronsBehaviorPharmaceutical PreparationsAddictionBehavioralIn VivoPropertySelf AdministrationPlayInsightProgramsIntravenousIntakeRewardsRattusMediatingCessation Of LifeMolecularSignal TransductionGenesMotivation
Grant awards (112)
Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration$3,657,715
U01 · FY2025 · DA
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder$3,027,897
UH3 · FY2025 · DA · contact PI
Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice$1,641,558
U01 · FY2025 · DA · contact PI
Cortical mechanisms of opioid reinforcement$787,594
R01 · FY2025 · DA · contact PI
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse$644,048
R01 · FY2025 · DA
Training Program in Substance Use Disorders$565,374
T32 · FY2025 · DA · contact PI
Mechanisms of nicotine reinforcement$417,916
R37 · FY2025 · DA · contact PI
Animal Models Core$299,242
P01 · FY2025 · DA · contact PI
Micro-RNAs in Stimulant and Opioid Action$281,385
P01 · FY2025 · DA · contact PI
Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration$3,653,101
U01 · FY2024 · DA
Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice$1,641,558
U01 · FY2024 · DA · contact PI
Training Program in Substance Use Disorders$565,334
T32 · FY2024 · DA · contact PI
Mechanisms of nicotine reinforcement$417,916
R37 · FY2024 · DA · contact PI
Animal Models Core$240,464
P01 · FY2024 · DA · contact PI
Micro-RNAs in Stimulant and Opioid Action$240,463
P01 · FY2024 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$25,222
P01 · FY2024 · DA · contact PI
Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration$3,648,488
U01 · FY2023 · DA
Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice$2,506,585
U01 · FY2023 · DA · contact PI
Training Program in Substance Use Disorders$553,178
T32 · FY2023 · DA · contact PI
Mechanisms of nicotine reinforcement$417,916
R37 · FY2023 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$266,963
P01 · FY2023 · DA · contact PI
Single cell transcriptomic and epigenomic changes during chronic HIV infection and cocaine self-administration$3,557,665
U01 · FY2022 · DA
Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice$2,641,224
U01 · FY2022 · DA · contact PI
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse$2,150,978
R01 · FY2022 · DA
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2022 · DA · contact PI
Habenular immune signaling and addiction$588,716
R01 · FY2022 · DA · contact PI
Training Program in Substance Use Disorders$399,448
T32 · FY2022 · DA · contact PI
Mechanisms of nicotine reinforcement$381,375
R37 · FY2022 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$266,963
P01 · FY2022 · DA · contact PI
Single cell brain transcriptome changes during chronic HIV infection and opiate use in conventional mice$2,654,681
U01 · FY2021 · DA · contact PI
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2021 · DA · contact PI
Habenular immune signaling and addiction$588,716
R01 · FY2021 · DA · contact PI
MicroRNAs in schizophrenia$421,237
R01 · FY2021 · MH · contact PI
Mechanisms of nicotine reinforcement$381,375
R37 · FY2021 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$240,939
P01 · FY2021 · DA · contact PI
Training Program in Substance Use Disorders$124,646
T32 · FY2021 · DA · contact PI
Development of novel therapeutics for opioid dependence$1,972,485
UH3 · FY2020 · DA · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$731,424
R01 · FY2020 · MH
Habenular immune signaling and addiction$588,716
R01 · FY2020 · DA · contact PI
MicroRNAs in schizophrenia$421,237
R01 · FY2020 · MH · contact PI
Nicotinic receptors and alcohol reinforcement$381,375
R01 · FY2020 · AA · contact PI
Mechanisms of nicotine reinforcement$381,375
R37 · FY2020 · DA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$378,541
R01 · FY2020 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$266,962
P01 · FY2020 · DA · contact PI
Role for Tas2Rs in opioid addiction$169,498
R37 · FY2020 · DA · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$82,540
R01 · FY2020 · MH
Development of novel therapeutics for opioid dependence$1,972,485
UG3 · FY2019 · DA · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$743,268
R01 · FY2019 · MH
Habenular immune signaling and addiction$588,716
R01 · FY2019 · DA · contact PI
MicroRNAs in schizophrenia$421,237
R01 · FY2019 · MH · contact PI
Mechanisms of nicotine reinforcement$381,375
R37 · FY2019 · DA · contact PI
Nicotinic receptors and alcohol reinforcement$381,375
R01 · FY2019 · AA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$378,541
R01 · FY2019 · DA · contact PI
Role for Circular RNAs in Compulsive Cocaine Intake$261,030
P01 · FY2019 · DA · contact PI
Development of novel therapeutics for opioid dependence$2,007,235
UG3 · FY2018 · DA · contact PI
Habenular immune signaling and addiction$735,894
R01 · FY2018 · DA · contact PI
Parallel Multimodal High-throughput screening to identify activators of the orexin receptors$598,887
R01 · FY2018 · MH
MicroRNAs in schizophrenia$421,237
R01 · FY2018 · MH · contact PI
Mechanisms of nicotine reinforcement$381,375
R37 · FY2018 · DA · contact PI
Nicotinic receptors and alcohol reinforcement$381,375
R01 · FY2018 · AA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$378,541
R01 · FY2018 · DA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$13,289
R01 · FY2018 · DA · contact PI
MicroRNAs in schizophrenia$421,237
R01 · FY2017 · MH · contact PI
Nicotinic receptors and alcohol reinforcement$381,375
R01 · FY2017 · AA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$378,541
R01 · FY2017 · DA · contact PI
Orexin receptor antagonists for drug addiction and panic disorder$91,578
U01 · FY2017 · NS · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$8,467
R01 · FY2017 · DA · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,652,504
P01 · FY2016 · DA
Nicotinic receptors and alcohol reinforcement$381,375
R01 · FY2016 · AA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$378,541
R01 · FY2016 · DA · contact PI
Mechanisms of nicotine reinforcement$339,805
R01 · FY2016 · DA · contact PI
Orexin receptor antagonist for drug addiction and panic disorder$104,000
U01 · FY2016 · NS · contact PI
Orexin receptor antagonists for drug addiction and panic disorder$91,578
U01 · FY2016 · NS · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,652,935
P01 · FY2015 · DA
Development of a5* nAChR positive allosteric modulators for tobacco dependence$1,201,163
R01 · FY2015 · DA · contact PI
Mechanisms of nicotine reinforcement$338,088
R01 · FY2015 · DA · contact PI
Orexin receptor antagonists for drug addiction and panic disorder$91,578
U01 · FY2015 · NS · contact PI
Development of a5* nAChR positive allosteric modulators for tobacco dependence$17,289
R01 · FY2015 · DA · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,685,235
P01 · FY2014 · DA
Development of a5* nAChR positive allosteric modulators for tobacco dependence$1,267,308
R01 · FY2014 · DA · contact PI
In Vivo Screening Strategies$636,352
P01 · FY2014 · DA · contact PI
Mechanisms of nicotine reinforcement$343,238
R01 · FY2014 · DA · contact PI
Orexin receptor antagonists for drug addiction and panic disorder$91,578
U01 · FY2014 · NS · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,624,668
P01 · FY2013 · DA
Development of a5* nAChR positive allosteric modulators for tobacco dependence$1,486,387
R01 · FY2013 · DA · contact PI
In Vivo Screening Strategies$590,422
P01 · FY2013 · DA · contact PI
Mechanisms of nicotine reinforcement$384,912
R01 · FY2013 · DA · contact PI
Orexin receptor antagonists for drug addiction and panic disorder$95,197
U01 · FY2013 · NS · contact PI
Mechanisms of nicotine reinforcement$92,761
R01 · FY2013 · DA · contact PI
Development of Orexin-1 Receptor Antagonists for Drug Addiction$1,699,491
P01 · FY2012 · DA · contact PI
Development of a5* nAChR positive allosteric modulators for tobacco dependence$1,552,792
R01 · FY2012 · DA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$427,815
R01 · FY2012 · DA · contact PI
Mechanisms of nicotine reinforcement$400,950
R01 · FY2012 · DA · contact PI
Development of a5* nAChR positive allosteric modulators for tobacco dependence$1,593,145
R01 · FY2011 · DA · contact PI
Development of Orexin-1 Receptor Antagonists to Prevent Drug Relapse$465,843
R01 · FY2011 · DA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$427,815
R01 · FY2011 · DA · contact PI
Mechanisms of nicotine reinforcement in mice$372,674
R01 · FY2011 · DA · contact PI
Scripps Florida Product Development Partnership for smoking cessation therapeutic$124,489
UH2 · FY2011 · DA
Role of noncoding RNAs in schizophrenia$429,525
R01 · FY2010 · MH
Role of MicroRNAs in the Mechanisms of Drug Dependence$425,230
R01 · FY2010 · DA · contact PI
Development of Orexin-1 Receptor Antagonists to Prevent Drug Relapse$419,854
R01 · FY2010 · DA · contact PI
Mechanisms of nicotine reinforcement in mice$335,883
R01 · FY2010 · DA · contact PI
Role of noncoding RNAs in schizophrenia$429,525
R01 · FY2009 · MH
Role of MicroRNAs in the Mechanisms of Drug Dependence$429,525
R01 · FY2009 · DA · contact PI
Development of Orexin-1 Receptor Antagonists to Prevent Drug Relapse$424,095
R01 · FY2009 · DA · contact PI
Mechanisms of nicotine reinforcement in mice$339,276
R01 · FY2009 · DA · contact PI
Role of noncoding RNAs in schizophrenia$429,525
R01 · FY2008 · MH
Development of Orexin-1 Receptor Antagonists to Prevent Drug Relapse$424,095
R01 · FY2008 · DA · contact PI
Role of MicroRNAs in the Mechanisms of Drug Dependence$381,800
R01 · FY2008 · DA · contact PI
Mechanisms of nicotine reinforcement in mice$339,276
R01 · FY2008 · DA · contact PI
Development of Orexin-1 Receptor Antagonists to Prevent Drug Relapse$432,750
R01 · FY2007 · DA · contact PI
Mechanisms of nicotine reinforcement in mice$346,200
R01 · FY2007 · DA · contact PI